Cargando…

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy

Pancreatic cancer (PaC) is resistant to immune checkpoint therapy, but the underlying mechanisms are largely unknown. In this study, we have established four orthotopic PaC murine models with different PaC cell lines by intra-pancreatic inoculation. Therapeutic examinations demonstrate that only tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jing, Jiang, Yuexu, Huang, Yue, Wang, Qiongling, Kaifi, Jussuf T., Kimchi, Eric T., Chabu, Chiswili Yves, Liu, Zhenguo, Joshi, Trupti, Li, Guangfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591363/ https://www.ncbi.nlm.nih.gov/pubmed/34768100 http://dx.doi.org/10.1016/j.tranon.2021.101262

Ejemplares similares

LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis
por: Liu, Xinjian, et al.
Publicado: (2021)

PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2019)

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth
por: Chabu, Chiswili, et al.
Publicado: (2017)

Author Correction: RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions
por: Kumar, Senthil R., et al.
Publicado: (2020)

RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions
por: Kumar, Senthil R., et al.
Publicado: (2020)

(18)F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer
por: Avella, Diego M., et al.
Publicado: (2020)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice
por: Li, Guangfu, et al.
Publicado: (2018)

Clog-free high-throughput microfluidic cell isolation with multifunctional microposts
por: Venugopal, Dilip, et al.
Publicado: (2021)

Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2020)

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol
por: Yang, Ming, et al.
Publicado: (2023)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
por: Deshaies, Isabelle, et al.
Publicado: (2010)

Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2016)

Pleural space infections after image-guided percutaneous drainage of infected intraabdominal fluid collections: a retrospective single institution analysis
por: Avella, Diego M, et al.
Publicado: (2015)

Cancer Immunotherapy and Delivery System: An Update
por: Yang, Ming, et al.
Publicado: (2022)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses
por: Suvilesh, Kanve N., et al.
Publicado: (2022)

Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance
por: Dong, Yong-Li, et al.
Publicado: (2021)

Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer
por: Nussbaum, Yulia I., et al.
Publicado: (2021)

Single Circulating-Tumor-Cell-Targeted Sequencing to Identify Somatic Variants in Liquid Biopsies in Non-Small-Cell Lung Cancer Patients
por: Barbirou, Mouadh, et al.
Publicado: (2022)

Omental infarction in the postpartum period: a case report and a review of the literature
por: Tachezy, Michael, et al.
Publicado: (2010)

Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study
por: Nance, Michael, et al.
Publicado: (2021)

Cavitation assisted endoplasmic reticulum targeted sonodynamic droplets to enhanced anti-PD-L1 immunotherapy in pancreatic cancer
por: Chen, Jifan, et al.
Publicado: (2022)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene
por: Kholod, Olha, et al.
Publicado: (2022)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Liu, Yanfeng, et al.
Publicado: (2022)

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
por: Kim, Victoria M., et al.
Publicado: (2019)

Transcriptomics Analysis Reveals New Insights into the Roles of Notch1 Signaling on Macrophage Polarization
por: Hans, Chetan P., et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy
por: Yoo, Byunghee, et al.
Publicado: (2019)

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
por: Liu, Xiangsheng, et al.
Publicado: (2021)

Retracted: Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8d7mitjdbf97cr5u0opilvd04g